Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has recently enhanced its financial foundation through successful equity financings and option exercises, with financing income significantly increasing to $284K for the quarter and $611K year-to-date, up from $85K and $144K, respectively. The company is strategically positioning itself for growth ahead of its full product launches planned for the U.S. and EU between 2026 and 2028, supported by a strengthened commercial team and an effective logistics partnership to ensure operational readiness. Additionally, the growing positive feedback from healthcare providers regarding the LIBERTY Endovascular Robotic System suggests a strong market potential, reinforcing the outlook for accelerated growth and justifying a premium valuation in anticipation of its upcoming product launches.

Bears say

Microbot Medical faces a multitude of risks that significantly contribute to a negative outlook on its stock, including potential delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into neuro and cardio markets. The company is also hindered by a lack of near-term profitability and reimbursement issues, which could erode hospital margins linked to existing procedural codes for its devices. Additionally, the absence of data from randomized controlled trials further complicates its ability to secure necessary approvals and achieve sustainable commercial uptake.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.